January 16th 2025

Published in American Chemical Society Pharmacology & Translational Science: Effective, but Safe? Physiologically Based Pharmacokinetic (PBPK)-Modeling-Based Dosing Study of Molnupiravir for Risk Assessment in Pediatric Subpopulations

Published in American Chemical Society Pharmacology & Translational Science: Effective, but Safe? Physiologically Based Pharmacokinetic (PBPK)-Modeling-Based Dosing Study of Molnupiravir for Risk Assessment in Pediatric Subpopulations

Recognising that treatment options for vulnerable paediatric populations with COVID-19 are limited to intravenous remdisivir, the CARE team at Helmholtz Centre for Infection Research (HZI, Germany) wanted to validate the assumption that oral molnupiravir should not be prescribed to under 18-year-olds, due to the potential for cartilage and bone toxicity, which would put normal paediatric development at risk.

Through the application of physiologically based pharmacokinetic (PBPK) modelling, the HZI team was able to show that to match the efficacy of oral molnupiravir seen in adults, a proportionately much higher dose would be needed in paediatric populations, substantially increasing the toxicity risk.

To learn more, click here: Effective, but Safe? Physiologically Based Pharmacokinetic (PBPK)-Modeling-Based Dosing Study of Molnupiravir for Risk Assessment in Pediatric Subpopulations